%0 Generic
%A Castiblanco-Delgado D.S.
%A Seija-Butnaru D.
%A Molina-Arteta B.M.
%8 2022
%@ 22562087
%U http://hdl.handle.net/10818/59963
%X Introduction Administering systemic lidocaine has been shown to deliver effective analgesia for both cancer-related and non-cancer pain. Adverse effects and toxicity are rare with controlled administration. Objective To report the results obtained after the indication to manage with IV lidocaine infusion to control neuropathic pain flares in 9 cancer patients. Methodology Observational, descriptive, case series-type study. A search was conducted in the files of the Pain and Palliative Care Service of the National Cancer Institute - Instituto Nacional de Cancerología - in Bogotá. Patients over 18 years old diagnosed with cancer, who experienced high intensity neuropathic pain and with the cognitive ability to rate their pain in a numerical analogue scale (NAS), without any absolute contraindications for the use of IV lidocaine were included; patients were assessed between September 27 and November 21, 2019. Results 9 patients experiencing a pain flare-up which was characterized as neuropathic were registered, of which 89 % had some improvement following the administration of an initial lidocaine bolus. After one hour, 60 % reported over 40% improvement in the initial NAS. After 24 hours all patients had experienced some improvement, with a reduction of 46% in the pain scale as compared to the baseline. Conclusions In this series of cases, the intravenous infusion of lidocaine as an option for the management of neuropathic pain flares seems to reduce pain intensity following the initial bolus administration. Copyright © 2021 Sociedad Colombiana de Anestesiología y Reanimación (S.C.A.R.E.).
%I Colombian Journal of Anesthesiology
%T Intravenous lidocaine in cancer-related neuropathic pain: case series
%T Lidocaína endovenosa en dolor neuropático relacionado con cáncer: serie de casos
%R 10.5554/22562087.e1004
%~ Intellectum